Women whose breast tumours stain 3+ for ERBB2 (meaning that strong complete membrane staining is seen in more than 10% of tumour cells) are most likely to respond to trastuzumab (Vogel et al, 2002; Mass et al, 2005) (reviewed by Tokunaga et al, 2006). This evidence concerns the gene ERBB2 and neoplasm.